Better evidence.
Better value.
Better decisions.
Decivalue is an AI-powered value decision platform designed to support HTA, economic evaluation, indirect treatment comparison, pricing, and reimbursement strategy. We help pharmaceutical companies and payers understand clinical value, economic value, uncertainty, and decision impact with greater clarity.
Value sits at the center of every healthcare decision.
Decivalue combines Decision and Value. It is built to structure and interpret clinical value, economic value, budget impact, reimbursement risk, and uncertainty in one decision-oriented framework. Starting from InsigHTA’s expertise in HTA, economic evaluation, indirect comparison, and P&R strategy, Decivalue aims to grow into a global AI-enabled decision platform.
Evidence-based decisions
We connect clinical evidence, comparative effectiveness, economic evaluation, and reimbursement pathways into structured decision-ready outputs.
AI-assisted analysis
AI supports evidence review, comparator landscape mapping, model assumption review, and dossier drafting, while experts validate the final interpretation.
Global HTA perspective
Decivalue begins with deep expertise in the Korean reimbursement environment, while remaining expandable to global HTA standards such as NICE, CADTH, PBAC, HAS, and other payer decision frameworks.
Supporting value demonstration and reimbursement strategy.
Decivalue is designed to go beyond information delivery. It supports analytical workflows and documentation that are directly relevant to HTA, pricing, reimbursement, and evidence strategy.
Economic Evaluation
Cost-effectiveness model structure, ICER interpretation, sensitivity analysis, uncertainty assessment, and payer-oriented model review.
Indirect Treatment Comparison
Feasibility assessment for NMA, MAIC, STC, comparator networks, evidence gaps, and indirect comparison strategy.
Pricing & Reimbursement Strategy
Pricing strategy, reimbursement risk, payer objections, value story development, and evidence alignment for market access.
An HTA decision workflow combining AI draft and expert review.
Decivalue’s long-term vision is to become a login-based AI platform that enables pharmaceutical companies and payers to make faster, more transparent, and more evidence-based value decisions.
Evidence Input
Upload or enter publications, clinical trial results, comparator information, cost data, and market access assumptions.
AI Structuring
AI structures PICO, evidence maps, comparator landscapes, model assumptions, key uncertainties, and potential evidence gaps.
Expert Validation
HTA experts review evidence quality, assumptions, uncertainty, payer relevance, and methodological validity.
Decision Output
Outputs are converted into value stories, reimbursement strategy, model review summaries, and report drafts.
Start making better value decisions with Decivalue.
Contact us to discuss HTA, economic evaluation, indirect comparison, pricing and reimbursement strategy, or AI-assisted decision support.